ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: For instance, PROTACs targeting the oncogenic fusion protein BCR-ABL1 have shown potential in overcoming resistance to kinase inhibitors in chronic myeloid leukemia (CML).